Evidence map›Paper›PMID 19111249›Full record

ReviewThe Lancet. Oncology2009

New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer.

Rahul Pannala, Ananda Basu, Gloria M Petersen, Suresh T Chari

3 registry-linked trialsAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Lancet. Oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 272 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
272citing papers in PubMed, 14 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05306028 phase2active not recruitingstarted 2022, after this paper: background citation

Administration of Metformin and Insulin to Pancreatic Cancer Related Diabetes Mellitus (Type 3c)

Ran2022Enrolled20Registered outcomes4Posted comparisons0ConditionsDiabete Mellitus, Pancretic CancerArmsMetformin or insulin treatment
PMID 25403204PMID 29775599PMID 28114552other papers from this trial
Open the trial in the graph
NCT02978547 phase2unknown statusnot on this mapstarted 2019, after this paper: background citation

The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma

TypeinterventionalSponsorBritish Columbia Cancer AgencyRan2019 to 2021Enrolled20ConditionsResectable Pancreatic Ductal AdenocarcinomaArmsMetformin Hydrochloride 500Mg Tablet
NCT04164602 unknown statusnot on this mapstarted 2019, after this paper: background citation

New Onset of DiabetEs in aSsociation With Pancreatic Cancer

TypeobservationalSponsorUniversity of PecsRan2019 to 2025Enrolled2,522ConditionsDiabetes Mellitus, Diabetes, Diabetes Mellitus, Type 2, Diabetes type2
3 · Its place in the literature

Who cites it

272 citing papers in PubMed, 14 syntheses or guidelines pooled it, 545 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Diets, Dietary Patterns, Single Foods and Pancreatic Cancer Risk: An Umbrella Review of Meta-Analyses.International journal of environmental research and public health · 2022
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Trial
  16. Article
  17. Article
  18. Article
  19. Review
  20. Prediagnostic prescription patterns in pancreatic cancer: a retrospective primary care cohort study.The British journal of general practice : the journal of the Royal College of General Practitioners · 2026
    Article

212 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Rahul PannalaMiles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, Rochester, MN, USA.
Ananda Basu
Gloria M Petersen
Suresh T Chari
Mayo Clinic in Arizona · US

Funding

Tissue CoreP50CA102701 · NCI · MAYO CLINIC ROCHESTER · PI PETERSEN, GLORIA M. · 2004 to 2018
$32.7M
Does Hyperglycemia Predict Pancreatic Cancer Diagnosis?R01CA100685 · NCI · MAYO CLINIC ROCHESTER · PI CHARI, SURESH T. · 2003 to 2006
$965k
NCI NIH HHS P50 CA 10270NCI NIH HHS P50 CA102701NCI NIH HHS R01 CA 100685NCI NIH HHS R01 CA100685
6 · The paper itself

Abstract

Pancreatic cancer has a dismal prognosis because cancer-specific symptoms occur only at an advanced stage. If the cancer is to be discovered early, screening will need to be done in asymptomatic individuals. Because the incidence of pancreatic cancer is low, screening for asymptomatic cancer in the general population is not feasible; therefore, screening will need to be restricted to people at high risk of this disease. The proportion of patients with pancreatic cancer who also have hyperglycaemia or diabetes has previously been under appreciated. New data show that up to 80% of patients are either hyperglycaemic or diabetic, both of which can be detected in the presymptomatic phase. Diabetes has been shown to improve after pancreatic-cancer resection, suggesting that diabetes is caused by the cancer. Conversely, older patients with new-onset diabetes have about an eight-times higher risk of having pancreatic cancer than the general population. Recognition of new-onset diabetes as an early manifestation of pancreatic cancer could lead to the diagnosis of asymptomatic, early-stage pancreatic cancer. However, primary type-2 diabetes is common in the general population and pancreatic cancer is relatively uncommon, and the two forms of diabetes are clinically indistinguishable. The success of a strategy using new-onset hyperglycaemia and diabetes as a screening tool to identify people with a high likelihood of having asymptomatic pancreatic cancer will depend largely on our ability to differentiate pancreatic-cancer-associated diabetes from the more common type-2 diabetes by use of a (serological) biomarker.

Indexed as

Early Detection of CancerDiabetes MellitusEndosonographyHumansPancreatic NeoplasmsTomography, X-Ray Computed

Identifiers

PMID19111249
PMCPMC2795483
OpenAlexW2155146717

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.